PMID- 26720300
OWN - NLM
STAT- MEDLINE
DCOM- 20170517
LR  - 20211204
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 100
IP  - 11
DP  - 2016 Nov
TI  - Pubertal Development in Pediatric Kidney Transplant Patients Receiving Mammalian 
      Target of Rapamycin Inhibitors or Conventional Immunosuppression.
PG  - 2461-2470
AB  - BACKGROUND: Data regarding the onset of puberty in children receiving mammalian 
      target of rapamycin (mTOR) inhibitors are limited. METHODS: Kidney transplant 
      patients aged <14 years were analyzed retrospectively to a maximum age of 18 
      years, with a minimal observation period of 1 year. Immunosuppression comprised 
      (1) standard CNI-based regimen or (2) low-exposure mTOR inhibitor with 
      reduced-exposure CNI, initiated either de novo or in the maintenance phase. 
      RESULTS: Of 108 children analyzed, 67 received an mTOR inhibitor (56 everolimus, 
      11 sirolimus) and 41 did not. The age at which girls reached Tanner stage P2 was 
      similar with mTOR inhibitor therapy (median 11.6 years) or without (median 11.1 
      years) (P = 0.262), as was age at stage B2 (median 11.6 vs. 11.2 years; P = 
      0.753). In boys, both the age of attaining Tanner stage P2 (median 12.9 vs. 13.0 
      years; P = 0.796) and Tanner stage G2 (median 13.1 vs. 12.9 years; P = 0.344) 
      were also similar with or without an mTOR inhibitor. Age at menarche in girls, 
      and age at spermarche in boys, did not differ between the 2 groups. CONCLUSIONS: 
      In this retrospective analysis, sexual maturation ages and reproductive hormone 
      levels were comparable in adolescent kidney transplant patients receiving 
      low-exposure mTOR inhibitors and reduced CNI therapy or conventional CNI-based 
      immunosuppression.
FAU - Forster, Julia
AU  - Forster J
AD  - 1 Department of Pediatric Nephrology, Hannover Medical School, Hannover, Germany. 
      2 Integrated Treatment and Research Center for Transplantation, Hannover Medical 
      School, Hannover, Germany. 3 Department of Medical Statistics, University Medical 
      Center Gottingen, Gottingen, Germany. 4 Department of Pediatric Hematology and 
      Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Ahlenstiel-Grunow, Thurid
AU  - Ahlenstiel-Grunow T
FAU - Zapf, Antonia
AU  - Zapf A
FAU - Mynarek, Martin
AU  - Mynarek M
FAU - Pape, Lars
AU  - Pape L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 3XMK78S47O (Testosterone)
RN  - 409J2J96VR (Androstenedione)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Androstenedione/blood
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - *Immunosuppression Therapy
MH  - Infant
MH  - *Kidney Transplantation
MH  - Male
MH  - Puberty/*physiology
MH  - Retrospective Studies
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
MH  - Testosterone/blood
EDAT- 2016/10/25 06:00
MHDA- 2017/05/18 06:00
CRDT- 2016/01/01 06:00
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/05/18 06:00 [medline]
PHST- 2016/01/01 06:00 [entrez]
AID - 10.1097/TP.0000000000001037 [doi]
PST - ppublish
SO  - Transplantation. 2016 Nov;100(11):2461-2470. doi: 10.1097/TP.0000000000001037.